Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.
Catherine L WetzelThomas Lee SuttonStuart GardinerMaryam FarinolaNathalie JohnsonJennifer R GarreauPublished in: Journal of surgical oncology (2021)
The loss of HER2-positivity following NAT is not associated with worse 5-year RFS or OS. We do not recommend retesting HER2 status following NAT for the purpose of clinical management; these patients should complete targeted adjuvant therapy.